Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Neurocrine Biosciences Hits Short Sale Stop Loss, Willis Towers Watson Achieves Short Sale Target

|Includes: NBIX, SPY, Willis Towers Watson Public Limited (WLTW)

This is an update to our latest model portfolio report, 35 Stocks for April 2017.

A short sale position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) hit a stop loss target in the theoretical models and will be assumed closed at the end of trading tomorrow. The spike in this low-quality stock occured after it announed that the FDA approved Ingrezza, the only product for treatment of adults with tardive dyskinesia (see CNBC story on NBIX). The stock is up 19.63% MTD.

A short sale position in Willis Towers Watson Public Limited Company (NASDAQ:WLTW) reached its short sale target in the theoretical model and will be assumed closed at the end of trading tomorrow. The stock is down -3.52% MTD for the assumed equivalent short sale gain.

MTD the S&P 500 is down -0.75%, the theoretical long models are down -1.25%, stocks in the theoretical short model are down -2.15% for the assumed inverse short sale gain, and the theoretical long/short model is up 0.91%.

Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in OR SHORT POSITION IN ANY STOCK MENTIONED over the next 72 hours.

Additional disclosure: There are limitations inherent in our theoretical model results, particularly with the fact that such results do not represent actual trading and they may not reflect the impact material economic and market factors might have had on our decision making if we were actually managing client money.